Choi Eun-Kyoung, Jang Ho-Cheol, Kim Jae-Hyung, Kim Hyun-Jin, Kang Ho-Cheol, Paek Yun-Woong, Lee Hyun-Chul, Lee Seung-Hoon, Oh Won-Mann, Kang In-Chol
Dental Science Research Institute, Chonnam National University Dental School, 300 Yongbong-Dong, Puk-Gu, Kwangju 500-757, South Korea.
Int Immunopharmacol. 2006 Jun;6(6):908-15. doi: 10.1016/j.intimp.2006.01.007. Epub 2006 Feb 3.
Nuclear factor-kappaB (NF-kappaB) is a transcription factor that plays crucial roles in inflammation and immunity. Understanding the positive and negative regulation of NF-kappaB activity is therefore of fundamental importance. A few previous studies reported that inhibition of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway enhances lipopolysaccharide (LPS)-induced activation of NF-kappaB. However, many aspects of the PI3K negative regulation of NF-kappaB activation remain to be clarified. The present study was conducted to shed light on cell-type specificity, stimulus specificity, and upstream mechanisms of the enhanced NF-kappaB activation by PI3K inhibitors. Gel shift assays showed that LY294002 (LY29) potently increased interleukin (IL)-1-induced NF-kappaB DNA binding in human monocytic THP-1 cells. Moreover, another PI3K inhibitor 3-methyladenine also strongly enhanced IL-1-induced NF-kappaB DNA binding, while LY303511, an inactive analogue of LY29, did not increase the NF-kappaB DNA binding. Compared with LY29, wortmannin (WM) effected only a marginal enhancement of NF-kappaB DNA binding. LY29 treatment also augmented tumor necrosis factor (TNF)-mediated NF-kappaB DNA binding. Furthermore, LY29, but not WM, increased cyclooxygenase (COX)-2 mRNA expression by IL-1 or TNF in THP-1 cells. Likewise, prostaglandin E2 production by IL-1 was increased by LY29, but not by WM. Western blot analysis demonstrated that IkappaB kinase (IKK) activation as well as IkappaB-alpha degradation and NF-kappaB nuclear translocation was elevated by LY29 and WM. Among the tested cell lines (HL-60, ECV304, Hep-2, and Molt-4), only HL-60, a promyelocytic cell line, showed enhanced NF-kappaB DNA binding by LY29. These results suggest that pharmacological inhibition of PI3K enhances the NF-kappaB-activating pathways by IL-1 through augmentation of IKK activation in myeloid/monocytic cells and the NF-kappaB enhancement is more robustly achieved by LY29 than by WM.
核因子-κB(NF-κB)是一种转录因子,在炎症和免疫中发挥关键作用。因此,了解NF-κB活性的正负调控至关重要。先前的一些研究报道,抑制磷脂酰肌醇3-激酶(PI3K)-Akt途径可增强脂多糖(LPS)诱导的NF-κB激活。然而,PI3K对NF-κB激活的负调控的许多方面仍有待阐明。本研究旨在阐明PI3K抑制剂增强NF-κB激活的细胞类型特异性、刺激特异性和上游机制。凝胶迁移试验表明,LY294002(LY29)能有效增加人单核细胞THP-1细胞中白细胞介素(IL)-1诱导的NF-κB与DNA的结合。此外,另一种PI3K抑制剂3-甲基腺嘌呤也强烈增强IL-1诱导的NF-κB与DNA的结合,而LY29的无活性类似物LY303511则不会增加NF-κB与DNA的结合。与LY29相比,渥曼青霉素(WM)对NF-κB与DNA结合的增强作用仅为边缘性。LY29处理还增强了肿瘤坏死因子(TNF)介导的NF-κB与DNA的结合。此外,LY29而非WM增加了THP-1细胞中IL-1或TNF诱导的环氧合酶(COX)-2 mRNA表达。同样,LY29增加了IL-1诱导的前列腺素E2生成,但WM没有。蛋白质印迹分析表明,LY29和WM均可提高IκB激酶(IKK)的激活以及IκB-α的降解和NF-κB的核转位。在所测试的细胞系(HL-60、ECV304、Hep-2和Molt-4)中,只有早幼粒细胞系HL-60显示LY29增强了NF-κB与DNA的结合。这些结果表明,PI3K的药理学抑制通过增强髓系/单核细胞中IKK的激活,增强了IL-1激活NF-κB的途径,并且LY29比WM更能有效地实现NF-κB的增强。